SLI
2.019,59
PKT
+11,20
PKT
+0,56
%
Werbung
Analysen zu SLI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
10.01.17 | UBS buy | UBS AG | |
09.01.17 | Novartis Hold | Deutsche Bank AG | |
09.01.17 | Holcim buy | Deutsche Bank AG | |
09.01.17 | Roche buy | Deutsche Bank AG | |
09.01.17 | UBS Underperform | Merrill Lynch & Co., Inc. | |
09.01.17 | UBS buy | Merrill Lynch & Co., Inc. | |
06.01.17 | Holcim buy | Deutsche Bank AG | |
06.01.17 | Givaudan buy | Deutsche Bank AG | |
06.01.17 | Holcim market-perform | Bernstein Research | |
06.01.17 | Richemont Neutral | Goldman Sachs Group Inc. | |
05.01.17 | Swiss Re market-perform | Bernstein Research | |
05.01.17 | Zurich Insurance Underperform | Bernstein Research | |
05.01.17 | Swiss Re overweight | JP Morgan Chase & Co. | |
05.01.17 | Zurich Insurance Neutral | JP Morgan Chase & Co. | |
04.01.17 | Nestlé buy | Deutsche Bank AG | |
04.01.17 | UBS overweight | Barclays Capital | |
04.01.17 | UBS overweight | Barclays Capital | |
03.01.17 | Roche overweight | JP Morgan Chase & Co. | |
03.01.17 | Novartis Neutral | JP Morgan Chase & Co. | |
28.12.16 | UBS buy | Goldman Sachs Group Inc. | |
23.12.16 | UBS buy | Kepler Cheuvreux | |
22.12.16 | Roche buy | UBS AG | |
21.12.16 | Roche buy | Deutsche Bank AG | |
21.12.16 | Nestlé buy | Baader Bank | |
21.12.16 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
19.12.16 | Novartis buy | Jefferies & Company Inc. | |
19.12.16 | UBS buy | Citigroup Corp. | |
19.12.16 | UBS buy | Citigroup Corp. | |
16.12.16 | Swiss Re Hold | Société Générale Group S.A. (SG) | |
15.12.16 | UBS buy | Kepler Cheuvreux | |
15.12.16 | UBS Reduce | Kepler Cheuvreux | |
14.12.16 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
14.12.16 | UBS Hold | Deutsche Bank AG | |
14.12.16 | UBS Hold | Deutsche Bank AG | |
14.12.16 | Nestlé Neutral | BNP PARIBAS | |
14.12.16 | Holcim Neutral | Merrill Lynch & Co., Inc. | |
13.12.16 | Nestlé buy | Deutsche Bank AG | |
13.12.16 | Novartis Hold | Deutsche Bank AG | |
13.12.16 | Swiss Re overweight | JP Morgan Chase & Co. | |
13.12.16 | Novartis overweight | JP Morgan Chase & Co. |